No Data
No Data
Illumina's Promising Growth Trajectory: Buy Rating Backed by Strategic Positioning and Market Innovations
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs
Grail 2024 Revenue Guidance Range Above Consensus
BofA Securities Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $120
Bernstein Maintains Illumina(ILMN.US) With Hold Rating
Sector Update: Health Care Stocks Fall Tuesday Afternoon
No Data